Since many types of human tumors are under severe hypoxia and set up a series of cascading events for survival, a signaling pathway to adapt to a hypoxic environment is regarded as potent target for antitumor drugs. We therefore genetically engineered U251 human glioma cells as stable host and a vector in which a placental alkaline phosphatase (PLAP) reporter gene is under the control of a VEGF promoter.
In the course of screening, we discovered several unique 12-membered macrolides, designated as pladienolides ( Fig.   1 ) which inhibit hypoxia-induced PLAP expression from the culture broth of Streptomyces platensis Mer-11107.
In this paper, we describe the taxonomy of the producing strain, and the fermentation, isolation and biological activities of pladienolides. The antitumor activities of pladienolides are reported in a subsequent paper.
Materials and Methods

Microorganisms
Strain Mer-11107 was isolated from a soil sample collected in Kanagawa, Japan, and was deposited at the 
Isolation
The isolation procedure for pladienolides is shown in Fig. 3 . The fermentation broth (10 liters) was extracted twice with 8 liters of n-BuOH. The crude extracts were concentrated in vacuo to give approximately 10g of brown syrup. The residues were then subjected to gel chromatography over Sephadex LH-20 (1,500ml) with THF-MeOH (1:1) as the eluent. The eluent was concentrated in vacuo to yield 3g of yellow syrup. The syrup was then chromatographed on a silica gel column (Wakogel C-200, 50g) and eluted with EtOAc-MeOH (9:1). The first bioactive fraction containing 1-3 and the second active fraction containing 4-7 were collected, separately. The first fraction was concentrated to obtain 25mg of a syrup residue. This residue was subjected to preparative 250mm) using a linear gradient of CH3CN-0.15% KH2PO4 buffer, at a flow rate of 10ml/minute. Fractionation was guided by UV absorbance at 240nm to afford three peaks in the order of 1, 2, and 3. After these fractions were concentrated in vacuo, the resulting aqueous solutions were subjected to preparative HPLC (YMC-Pack ODS-AM at a flow rate of 10ml/minute. Each fractions containing pure piadienolides were freeze-dried respectively, yielding 1 (1.2mg), 2 (6.0mg), and 3 (0.3mg).
The second fraction was combined to give 16mg of a syrup residue. Using repeated reversed-phase chromatography in analogous manner as mentioned above, the second fraction provided 4 (1.8mg), 5 (1.0mg), 6 (0.1mg), and 7 (0.2mg). Seven pladienolide analogues were evaluated in a PLAP reporter assay (Table 4 ). The potency was classified into Lack of an acetyl group dramatically decreased the activity by more than two orders of magnitude, as seen in pladienolides A (1), F (6), and G (7). Addition of a hydroxyl group at R2 or R3 position of 2 decreased the activity. Since the activity of 4 was fifteen times stronger than that of pladienolide E (5), hydroxylation of the R2 position was more significant than that of the R3 position. Pladienolide B (2) was the strongest, with the order of the strength of VEGF-PLAP inhibitory activity as follows:
2>4>3>5>1>6>7.
Growth-inhibitory Activity
Low-density conditions were used to evaluate growth inhibitory activity. The cell density was different from that used for the VEGF-PLAP assay. The results are shown in Table 4 . Pladienolides also inhibited the growth of U251 cells. The order of the strength of growth inhibition was the same as that for VEGF-PLAP inhibitory activity. Each IC50 value of growth inhibition was slightly higher than that VEGF-PLAP, indicating that pladienolides inhibit both cancer cell growth and hypoxia signals.
Discussion
Hypoxia signals are currently thought to be an attractive target for anticancer therapy14). Since hypoxia-inducible factor (HIF) is a master regulator of hypoxia signals, many groups have been searching for small molecules that might inhibit the HIF pathway14,15), and although several compounds have been found to inhibit the HIF pathway16), they do not appear to be sufficiently potent to act as anticancer agents. Therefore, a novel HIF-pathway inhibitor with high potency is needed to regulate tumors in a hypoxic microenvironment.
To search for HIF pathway inhibitors, we constructed a VEGF-PLAP system and screened fermented microbial broth libraries. After screening approximately 27,000 samples, we isolated seven novel macrolides, which we designated as pladienolides. These seven pladienolide analogues allowed us to elucidate the structure-activity relationships (SARs) between the structures and the inhibition activity against hypoxia-induced VEGF expression and cell proliferation using a U251 cell. Pladienolides also showed strong antitumor effects in human tumor xenograft models in mice. Details of these antitumor effects of pladienolides will be described in a subsequent paper17). 
